Growth Investors Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. Revenue Forecasts ... - Yahoo New Zealand News
CCCC Stock | USD 4.55 0.36 8.59% |
About 60% of all C4 Therapeutics' shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding C4 Therapeutics suggests that some traders are interested. The current market sentiment, together with C4 Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use C4 Therapeutics stock news signals to limit their universe of possible portfolio assets.
CCCC |
Growth Investors Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. Revenue Forecasts ... Yahoo New Zealand News
Read at news.google.com
C4 Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards C4 Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
C4 Therapeutics Fundamental Analysis
We analyze C4 Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
C4 Therapeutics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
C4 Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with C4 Therapeutics stock to make a market-neutral strategy. Peer analysis of C4 Therapeutics could also be used in its relative valuation, which is a method of valuing C4 Therapeutics by comparing valuation metrics with similar companies.
Peers
C4 Therapeutics Related Equities
GLUE | Monte Rosa | 13.72 | ||||
PRLD | Prelude Therapeutics | 7.14 | ||||
IPSC | Century Therapeutics | 5.52 | ||||
NRIX | Nurix Therapeutics | 4.15 | ||||
ARVN | Arvinas | 2.85 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
FHTX | Foghorn Therapeutics | 2.57 | ||||
EWTX | Edgewise Therapeutics | 2.48 | ||||
RZLT | Rezolute | 1.00 | ||||
STTK | Shattuck Labs | 0.92 | ||||
KYMR | Kymera Therapeutics | 0.02 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
MLYS | Mineralys Therapeutics, | 2.59 |
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |